The regenerative capacity of the mammalian heart is insufficient to recover from myocardial infarction. Stem cells are currently considered as a promising and valuable tool to replace the, often large, loss of contractile tissue. One of the bottlenecks hampering fast clinical application is the large amount of cells required to replace a single damaged region combined with an appropriate strategy to succeed in homogeneous repair. A second class of major cardiac disorders for which stem cell therapy might be fruitful and would require less cells for repair, are chronic rhythm disorders. In this area, most research has been focused on stem-cell based biological pacemakers, but increasing amounts of data on AV nodal repair appear in literature. Both therapies, in principle, could eventually replace current instrumentation with electronic pacemakers. Finally, an emerging field of interest explores transplantation of stem cells expressing specific ion channels aiming at suppression of focal arrhythmias, providing an alternative strategy for surgical and catheter-mediated ablation. Since in this second class of applications the number of transplanted cells required may be relatively low, effective clinical therapy may be within close range. Here, we will review recent achievements in the fields of stem-cell based biological pacemakers, AV nodal repair and biological ablation.

Download full-text PDF

Source
http://dx.doi.org/10.2174/157488809787169066DOI Listing

Publication Analysis

Top Keywords

stem cell
8
cell therapy
8
stem cells
8
cells required
8
second class
8
stem-cell based
8
based biological
8
biological pacemakers
8
nodal repair
8
cells
5

Similar Publications

Tension-induced organelle stress: an emerging target in fibrosis.

Trends Pharmacol Sci

January 2025

Department of Surgery, University of California, San Francisco, San Francisco, CA, USA; Center for Bioengineering and Tissue Regeneration, University of California, San Francisco, San Francisco, CA, USA; UCSF Helen Diller Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA; Department of Radiation Oncology, Eli and Edythe Broad Center for Regeneration Medicine and Stem Cell Research, University of California, San Francisco, San Francisco, CA, USA.

Fibrosis accounts for approximately one-third of disease-related deaths globally. Current therapies fail to cure fibrosis, emphasizing the need to identify new antifibrotic approaches. Fibrosis is defined by the excessive accumulation of extracellular matrix (ECM) and resultant stiffening of tissue stroma.

View Article and Find Full Text PDF

Tyrosine Kinase Inhibitor Treatment Patterns in Patients With Chronic-Phase Chronic Myeloid Leukemia: A Single Center Data From China.

Clin Lymphoma Myeloma Leuk

December 2024

Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China; Hematology Center, Peking University People's Hospital, Qingdao, China. Electronic address:

Aim: To describe tyrosine kinase inhibitor (TKI) treatment patterns and analyze co-variates of TKI switch for chronic myeloid leukemia (CML) patients in a center from China.

Methods: A retrospectively study was designed to analyze TKI switching patterns, reasons and associated covariates in patients with CP-CML.

Results: 1766 patients receiving initial imatinib (n = 1374), nilotinib (n = 254), dasatinib (n = 63) and flumatinib (n = 75) therapy were retrospectively interrogated.

View Article and Find Full Text PDF

The hidden weavers: A review of DNA/RNA R-loops in stem cell biology and therapeutic potential.

Int J Biol Macromol

January 2025

Stomatological Hospital, School of Stomatology, Southern Medical University, Guangzhou 510280, Guangdong, China. Electronic address:

R-loops, three-stranded nucleic acid structures composed of RNA-DNA hybrids, are increasingly recognized as central regulators of genomic stability and transcription. These structures play critical roles across various cellular processes, including DNA replication, repair, and gene regulation, with significant implications for stem cell biology and disease pathogenesis. This review comprehensively explores the molecular underpinnings of R-loop formation, emphasizing the dual nature of R-loops in both facilitating normal cellular functions and contributing to genomic instability.

View Article and Find Full Text PDF

Surface coating nanoarchitectonics for optimizing cytocompatibility and antimicrobial activity: The impact of hyaluronic acid positioning as the outermost layer.

Int J Biol Macromol

January 2025

Department of Chemistry, State University of Maringá, Maringá, PR, Brazil; Laboratory of Materials, Macromolecules, and Composites, Federal University of Technology - Paraná, Apucarana, PR, Brazil; National Institute for Materials Advancement, Pittsburg State University, Pittsburg, KS, USA; Department of Chemistry, Pittsburg State University, Pittsburg, KS, USA. Electronic address:

Polyelectrolyte multilayers (PEMs) based on hyaluronic acid (HA) and poly (diallyldimethylammonium chloride) (PDDA) were deposited on oxidized polystyrene (PS) via the layer-by-layer (LbL) method. The X-ray photoelectron spectroscopy (XPS) confirmed the PEM deposition on PS, and atomic force microscopy (AFM) indicated that the surface roughness of PS also increased after PEM deposition. The PEMs significantly enhanced PS wettability, reducing the contact angle from 73° on PS to 24° on PDDA-terminated (PDDA/HA) PEM (2.

View Article and Find Full Text PDF

c-FLIP/Ku70 complex; A potential molecular target for apoptosis induction in hepatocellular carcinoma.

Arch Biochem Biophys

January 2025

Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran; Experimental Cancer Medicine, Institution for Laboratory Medicine, Karolinska Institute, Stockholm, Sweden. Electronic address:

Hepatocellular carcinoma (HCC) is one of the most lethal malignancies worldwide and the most common form of liver cancer. Despite global efforts toward early diagnosis and effective treatments, HCC is often diagnosed at advanced stages, where conventional therapies frequently lead to resistance and/or high recurrence rates. Therefore, novel biomarkers and promising medications are urgently required.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!